Investors
A proven track record of value creation
Our robust business model provides significant opportunities to drive growth and deliver value for investors.
Together we’re building a leading global pharmaceutical business
By putting better health within reach of patients every day through investment, innovation and diversification, we’re enhancing our portfolio responsibly and creating strong shareholder returns.
H1 2025 Interim Results
Watch Riad Mishlawi, CEO
Latest stories
Featured
Hikma delivers a solid H1 performance and re-affirms expectations for strong growth in the second half
Press Release, Financial Results
07 August 2025
- Hikma and Celltrion strengthen partnership to expand biosimilar access in MENA Press Release, Business Development 06 October 2025 Hikma and Celltrion strengthen partnership to expand biosimilar access in MENA
- Inspiring women of Hikma - Meet Christine Schneider, General Manager, Hikma Germany Story, Life at Hikma 06 October 2025 Inspiring women of Hikma - Meet Christine Schneider, General Manager, Hikma Germany
- Driving pharmaceutical excellence and growth in Pavia: A Q&A with Roberto Gagliano, General Manager, Hikma Italia Insight, Life at Hikma 03 October 2025 Driving pharmaceutical excellence and growth in Pavia: A Q&A with Roberto Gagliano, General Manager, Hikma Italia
- Hikma and Richter receive FDA approval for denosumab biosimilars EnobyTM (denosumab- qbde) and XtrenboTM (denosumab- qbde) referencing Prolia® and Xgeva® respectively Press Release, Product 29 September 2025 Hikma and Richter receive FDA approval for denosumab biosimilars EnobyTM (denosumab- qbde) and XtrenboTM (denosumab- qbde) referencing Prolia® and Xgeva® respectively
